


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in this application.


**Listing of Claims:**

Claims 1-43 (cancelled).

Claim 44 (currently amended): A pharmaceutical formulation comprising:  
a benzamide derivative represented by formula (1):



wherein A represents a structure shown by ~~any one of~~ formula (2):



or a pharmaceutically acceptable salt thereof;

~~an excipient selected from the group consisting of lactose, lactose anhydride, D-mannitol, corn starch, and crystalline cellulose;~~

~~a lubricant selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, and talc;~~

~~a disintegrant selected from the group consisting of partly pregelatinized starch, carmellose calcium and carboxymethylstarch sodium; and~~

at least one member selected from the group consisting of an amino compound and an inorganic base,

wherein


the amino compound is ~~at least one member selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine-L-glutamate, and carbachol; and~~

the inorganic base is at least one member selected from the group consisting of sodium carbonate, potassium carbonate, ~~ammonium carbonate, sodium bicarbonate, and potassium bicarbonate, sodium hydroxide, disodium phosphate, and ammonia.~~


Claim 45 (cancelled).

Claim 46 (currently amended): A pharmaceutical formulation comprising:

a benzamide derivative represented by formula (1):



wherein A represents a structure shown by ~~any one of~~ formula (2):



or a pharmaceutically acceptable salt thereof;

at least one solvent ~~that is selected from the group consisting of propylene glycol, dimethylacetamide, and a polyethylene glycol;~~ and

at least one member selected from the group consisting of an organic acid salt, an amino compound and an inorganic base;  
wherein

the organic acid salt is at least one member selected from the group consisting of monosodium fumarate, sodium alginate, sodium dehydroacetate, sodium erythorbate, and trisodium citrate;

the amino compound is at least one member selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine L-glutamate, and carbachol; and

the inorganic base is at least one member selected from the group consisting of sodium carbonate, ~~potassium carbonate,~~ ammonium carbonate, sodium bicarbonate, potassium bicarbonate, ~~sodium hydroxide,~~ disodium phosphate, and ammonia.

Claim 47 (previously presented): The pharmaceutical formulation according to claim 46  
wherein

the at least one solvent is polyethylene glycol 400; and

the formulation is maintained at a pH in the range of about 7 to about 11 through addition of an acid or a base.

Claim 48 (previously presented): The pharmaceutical formulation according to claim 47 wherein the acid is hydrochloric acid and the base is sodium hydroxide.

Claim 49 (cancelled).